How to carry out the treatment of lupus erythematosus in the pediatric system
Time of Update: 2022-10-02
For severe lupus nephritis, such as diffuse proliferative nephritis and central nervous system symptoms, methylprednisolone shock therapy can be used at a dose of 15 to 30 mg/kg, up to a maximum of 1 g, once a day for 3 days, and then switched to prednisone orally.
Inhalant pins change hands, and domestic brands rise! 13 products break through the new medical insurance
Time of Update: 2022-10-01
In the first half of 2022, the brand pattern of sevoflurane for terminal inhalation in public hospitals in key provinces and cities As of now, a total of 5 products have been included in the national collection, and the suspensions for inhalation and terbutaline sulfate atomized inhalation solutions are TOP10 products.
FDA approves dual-targeted type 2 diabetes drug Mounjaro, which can help non-diabetic patients lose 22.5
Time of Update: 2022-08-11
com/story/5571833 Leave a comment here The FDA approved Eli Lilly's once-weekly dual GIP and GLP-1 receptor agonist Mounjaro (tirzepatide) to improve glycemic control in adults with type 2 diabetes .
Ji Xiaoyun/Rao Zihe/Yang Haitao/Huang Ailong/Jin Aishun Joint Team Reveals Immune Escape Mechanism of SARS-CoV-2 Omicron Variant Strain
Time of Update: 2022-05-20
COVID-19 , caused by SARS-CoV-2 , poses an unprecedented threat to global public health , especially the newly emerged Omicron mutant strains are widely circulating around the world, continuously givi
The CD39 monoclonal antibody of Kewang Pharma is approved for clinical use in China
Time of Update: 2022-03-09
By blocking the ATPase activity of the CD39 protein, ES002 can inhibit the production of adenosine while maintaining the level of extracellular ATP with pro-inflammatory effects, thereby creating an immune microenvironment conducive to anti-tumor .
Large chains accelerate the layout of "dual-channel" pharmacies
Time of Update: 2022-03-03
86 new drugs are included in the "dual channel", which is good for pharmacies86 new drugs are included in the "dual channel", which is good for pharmaciesOn February 18, the Hunan Provincial Medical Insurance Bureau issued a public announcement, announcing that 86 new drugs in Hunan this year were included in the "dual-channel" single-line payment management .
1.2 million injections of anti-cancer drugs may miss medical insurance
Time of Update: 2021-12-08
It is worth noting that from November 10 until the end of the medical insurance negotiations, the representative of Fosun Kate, a manufacturer of "sky-priced anti-cancer drugs" with a high price of 1.
Pioneer Pharmaceuticals completes the first patient administration in the Phase III clinical trial of Prokalutamide in the treatment of hospitalized patients with new crowns in the United States
Time of Update: 2021-11-16
Tong Youzhi, Founder, Chairman and CEO of Pioneer Pharmaceuticals, said: "I am very pleased to announce that the registered Phase III clinical trial of Prokalamide for the treatment of hospitalized patients with severe new coronary disease has completed the first patient enrollment in the United States .
The State Council requires the planning and improvement of medical security: by 2025, there will be more than 500 centralized drug products
Time of Update: 2021-10-10
Shi Zihai, deputy director of the National Medical Security Administration, stated at the briefing that during the "14th Five-Year Plan" period, the scope of centralized procurement of medicines and high-value medical consumables will be further expanded, allowing the public to use more new and good medicines .
Targeting CCR4 "Moglizumab" submits a listing application in China
Time of Update: 2021-08-09
Public information shows that mogamulizumab is a CCR4 targeting antibody that has been approved by the FDA for breakthrough therapy and priority review, and has been approved for marketing in the United States for the treatment of mycosis fungoides ( MF) or Sezari syndrome (SS) in adult patients .
Retrieved August 8, 2018, from https:// -announces-fda-approval-of-poteligeo-mogamulizumab-kpkc-for-the-treatment-of-mycosis-fungoides-and-sezary-syndrome-300694118.
The second batch of key projects of China's drug regulatory scientific action plan released
Time of Update: 2021-08-09
After two years of hard work, the first batch of key projects has achieved important results, and 103 new regulatory tools, new methods, and new standards have been studied and formulated , 31 of which have been released .
Kangchen Pharmaceutical's net profit fell by 30%. Is it the "pot" of the epidemic or the "fruit" of a single product
Time of Update: 2021-07-14
According to the 2020 semi-annual report of Kangchen Pharmaceutical, the operating income during the reporting period was 348 million yuan, a year-on-year decrease of 35.
053 billion yuan; and agkistrodon hemagglutinin for injection achieved revenue in 2020 Operating income was 792 million yuan, accounting for 98% of the annual revenue .
Junshengtai HTD1801 Primary Biliary Cholangitis Phase II Clinical Trial of the First Patient Enrolled in the Group
Time of Update: 2021-07-06
On this basis, We are very much looking forward to the positive results of the Phase II clinical trial for primary biliary cholangitis, which will bring safer and more effective treatment options for patients .
All 3 specifications of Duloxetine Hydrochloride Enteric-coated Capsules of Enhua Pharmaceutical have been approved
Time of Update: 2021-06-29
On the 18th, Enhua Pharmaceutical announced that the company has recently obtained the "Drug Registration Certificate" for the psychotropic drug duloxetine hydrochloride enteric-coated capsules 20mg, 30mg, and 60mg approved and issued by the National Medical Products Administration .
Takeda Pharmaceutical’s one-type or one-year “rare” or original sin
Time of Update: 2021-04-18
Medical Network News on April 13 One species, one year off Recently, Takeda Pharmaceutical announced in an open letter from the Hypoparathyroidism Association, broader hypoparathyroidism patients and the medical community that the supply of Natpara 100 micrograms (mcg) may be interrupted as early as the week of April 5th.